Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.
Company profile
Ticker
PRNB
Exchange
Website
CEO
Martin Babler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
263487603
PRNB stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
8 Oct 20
EFFECT
Notice of effectiveness
30 Sep 20
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 20
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 20
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Sep 20
POS AM
Prospectus update (post-effective amendment)
28 Sep 20
25-NSE
Exchange delisting
28 Sep 20
8-K
Completion of Acquisition or Disposition of Assets
28 Sep 20
SC 14D9/A
Tender offer solicitation (amended)
28 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
28 Sep 20
Latest ownership filings
SC 13G/A
Cormorant Asset Management, LP
16 Feb 21
SC 13D/A
GLAXOSMITHKLINE PLC
1 Oct 20
4
Shawn Tomasello
28 Sep 20
4
Patrick Machado
28 Sep 20
4
Simeon George
28 Sep 20
4
Shao-Lee Lin
28 Sep 20
4
Daniel J. Becker
28 Sep 20
4
Alan Colowick
28 Sep 20
4
Stefani Wolff
28 Sep 20
4
Dolca Thomas
28 Sep 20
Financial summary
Quarter (USD) | Jun 20 | Mar 20 | Sep 19 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 171.05 mm | 171.05 mm | 171.05 mm | 171.05 mm | 171.05 mm | 171.05 mm |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 3.37 mm | 8.98 mm | 4.91 mm |
Cash used (since last report) | n/a | n/a | n/a | 154.88 mm | 412.84 mm | 225.48 mm |
Cash remaining | n/a | n/a | n/a | 16.17 mm | -241.79 mm | -54.43 mm |
Runway (months of cash) | n/a | n/a | n/a | 4.8 | -26.9 | -11.1 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|